What is AnaBios?
AnaBios, based in San Diego, California, is dedicated to advancing the safety and efficacy of new therapeutic compounds. Leveraging advanced, human-focused translational technologies, the company targets critical areas such as cardiac disease, pain, and itch. AnaBios collaborates with Fortune 500 biotech firms, Contract Research Organizations (CROs), and academic institutions, while also advancing its internal drug discovery pipeline through in-licensed programs from pharmaceutical partners.
How much funding has AnaBios raised?
AnaBios has raised a total of $12.3M across 3 funding rounds:
Series A
$2M
Series B
$10M
Debt
$350K
Series A (2011): $2M with participation from Tech Coast Angels
Series B (2016): $10M led by Principia SGR
Debt (2020): $350K supported by PPP
Key Investors in AnaBios
Tech Coast Angels
Tech Coast Angels is a prominent angel investment group known for backing early-stage companies, particularly those in technology and life sciences within Southern California.
Principia SGR
Principia SGR is an Italian venture capital firm with a dedicated focus on the healthcare sector, investing in startups and SMEs to provide growth capital and support innovation.
PPP
Public-Private Partnership
What's next for AnaBios?
The substantial enterprise-level funding positions AnaBios for accelerated growth and expanded research and development initiatives. This capital injection is expected to fuel the advancement of its pipeline, potentially leading to key clinical milestones and strategic partnerships. The company's focus on high-impact therapeutic areas suggests a trajectory aimed at addressing significant market gaps and establishing a strong presence in the biopharmaceutical sector.
See full AnaBios company page
